5Lesem MD, Zajeeka JM, Swift RH, et al. Intramuscular ziprasidone,2 mg versus 10 rag, in the short term management of agitated psychotic patients[J]. J Clin Psychiatry,2001,62( 1 ) : 12-18.
6Miceli JJ, Anziano R J, Bobarge L, et al. The effect of car-bamazepine on the steady-state pharmacokinetics of ziprasi-done in healthy volun- teers [ J ]. Br J Clin pharmacol,2000,49 ( suppl1 ) : 65 S-70 S.
7Swainston HT, Scott LJ. Ziprasidone : a veview of its use in schizophre- nia and schizoaffective disorder[ J]. CNS Drugs,2006,20( 12 ) :1027- 1052.
8Meyer JM, Davis VG, Goff DC, et al. Change in metabdic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial:Prospective data fram phase 1 [ J ]. Schizophrenia Research, 2008,101 ( 1 ) :273-286.
9Greenbtrg WM, CitromeL. Ziprasidone for schizophrenia and bipolar disorder, a review of clinical trials [ J ]. CNS Drug Rev ,2007,13 (2) : 137-177.
10Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsy- chotic drug for the treatment of schizophrenia[ J ]. Clin Ther,2002, 24( 1 ) :21-37.
